Shanghai, China, Jul 8 (EFE).- Antibodies against the SARS-CoV-2 coronavirus can last up to 12 months in more than 70 percent of patients who have overcome the Covid-19, according to a study made public Thursday by the country’s state media.
The study also said vaccinations can “effectively restrict the spread” of the coronavirus by promoting an immune response similar to the way human bodies generate human antibodies against live viruses, according to the China Daily newspaper.
The study was carried out by a subsidiary of state pharmaceutical company Sinopharm – which produces two of the vaccines approved by the Chinese government – and the National Research Center for Translational Medicine at Jiaotong University in Shanghai.
Some 1,800 convalescent plasma samples were collected from 869 people who overcame Covid-19 in the last year in Wuhan, the city where the first global outbreak of the coronavirus was registered in December 2019.
Researchers checked the amount in these samples of RBDIgG, an antibody that shows the strength of immunity against the virus, the newspaper said.
According to results, antibody levels fell to 64.3 percent in nine months compared to the level when patients contracted the virus, then stabilized until the 12th month.
The immune response was stronger in men than in women during the early stages of the infection, but the difference faded over time, almost disappearing after a year.
People in the 18 to 55 age group developed higher levels of antibodies.
According to China’s National Biotechnology Group – the Sinopharm subsidiary that prepared it – the study is the most extensive of those that have verified the continuity of the immune response in patients recovered from Covid-19. EFE